Research ArticleArticle
Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors
Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402
Stefan Bidula
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Izzuddin Bin Nadzirin
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Marco Cominetti
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Harry Hickey
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Sean A. Cullum
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Mark Searcey
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Ralf Schmid
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
Samuel J. Fountain
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
5-BDBD Antagonist Action through an Allosteric Site on P2X4
Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 1, 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402
Research ArticleArticle
5-BDBD Antagonist Action through an Allosteric Site on P2X4
Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 1, 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement